Niki Arrowsmith06.06.12
As far as emerging medtech markets go, what comes to mind are usually China, India and Brazil, likely in that order. Terumo BCT, with funding from its parent company Terumo Corporation, will be building a new manufacturing facility in Vietnam. Terumo Corp. is committing $100 million to both this project and a new facility in the United States.
Terumo BCT, a blood component and cellular technologies company, was known as Caridian BCT before being purchased by Tokyo, Japan-based Terumo Corp. Terumo BCT is headquartered in Lakewood, Colo., and is the only subsidiary of Terumo Corp with headquarters outside Japan. Terumo Corp. has regional headquarters in Brussels, Belgium; Buenos Aires, Argentina; Hong Kong, China; and Tokyo.
“This is an exciting time for our organization. In just 12 months, we combined the businesses of CaridianBCT and Terumo Transfusion to emerge as Terumo BCT,” said David Perez. “With Terumo’s investment we are able to expand our global capabilities and footprint to be even more responsive to the demands of the marketplace. This investment demonstrates Terumo's commitment to the industry, to our organization and to better serve our current and future customers.” Perez is president and CEO of Terumo BCT, and serves as chairman of Terumo Corp.’s Blood Management Business Division.
The new U.S. facility will be located in Colorado, and will receive its funding around the same time the Vietnam facility sees the beginning of construction in early 2013. The bulk of the funding will go to the Vietnam facility, with only $6 million being funneled to Colorado. The land on which the Vietnam facility is to be built is approximately 25 acres.
Koji Nakao, Terumo Corp. chairman and representative director, said that this investment is part of the company’s mission to “contribute to society through healthcare.”
Terumo BCT designs and manufactures systems for apheresis collections, manual and automated whole blood processing, and pathogen reduction coupled with technologies in therapeutic apheresis and cell processing.
Terumo BCT, a blood component and cellular technologies company, was known as Caridian BCT before being purchased by Tokyo, Japan-based Terumo Corp. Terumo BCT is headquartered in Lakewood, Colo., and is the only subsidiary of Terumo Corp with headquarters outside Japan. Terumo Corp. has regional headquarters in Brussels, Belgium; Buenos Aires, Argentina; Hong Kong, China; and Tokyo.
“This is an exciting time for our organization. In just 12 months, we combined the businesses of CaridianBCT and Terumo Transfusion to emerge as Terumo BCT,” said David Perez. “With Terumo’s investment we are able to expand our global capabilities and footprint to be even more responsive to the demands of the marketplace. This investment demonstrates Terumo's commitment to the industry, to our organization and to better serve our current and future customers.” Perez is president and CEO of Terumo BCT, and serves as chairman of Terumo Corp.’s Blood Management Business Division.
The new U.S. facility will be located in Colorado, and will receive its funding around the same time the Vietnam facility sees the beginning of construction in early 2013. The bulk of the funding will go to the Vietnam facility, with only $6 million being funneled to Colorado. The land on which the Vietnam facility is to be built is approximately 25 acres.
Koji Nakao, Terumo Corp. chairman and representative director, said that this investment is part of the company’s mission to “contribute to society through healthcare.”
Terumo BCT designs and manufactures systems for apheresis collections, manual and automated whole blood processing, and pathogen reduction coupled with technologies in therapeutic apheresis and cell processing.